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Abstract
Background: A long-term analysis by the Early Breast Cancer Trialist Group (EBCTG) revealed a strong correlation
between local control and cancer-specific mortality. MicroRNAs (miRs), short (20–25 nucleotides) non-coding RNAs,
have been described as prognosticators and predictors for breast cancer in recent years. The aim of the current study
was to identify miRs that can predict local control after breast conserving therapy (BCT) in early stage breast cancer.
Results: Clinical data of 46 early stage breast cancer patients with local relapse after BCT were selected from the
institutional database. These patients were matched to 101 control patients showing identical clinical features but
without local relapse. The study was conducted in two steps. (1) In the pilot study, 32 patients (16 relapses versus 16
controls) were screened for the most de-regulated microRNAs (= candidate microRNAs) in a panel of 1250 miRs by
microarray technology. Eight miRs were found to be significantly de-regulated. (2) In the validation study, the
candidate microRNAs were analyzed in an independent cohort of 115 patients (30 relapses versus 85 controls) with
reverse transcription quantitative polymerase chain reaction (RT-qPCR). From these eight candidates, hsa-miR-375
could be validated. Its median fold change was 2.28 (Mann-Whitney U test, corrected p value = 0.008). In the log-rank
analysis, high expression levels of hsa-miR-375 correlated with a significantly higher risk of local relapse (p = 0.003). In
a multivariate analysis (forward stepwise regression) including established predictors and prognosticators, hsa-miR-375
was the only variable that was able to distinguish the statistical significance between relapse and control groups (raw
p value = 0.000195 HR = 0.76, 95 % CI 0.66–0.88; corrected p value = 0.005).
Conclusions: Hsa-miR-375 predicts local control in patient with early stage breast cancer, especially in estrogen
receptor α (ER-α)-positive patients. It can therefore serve as an additional molecular marker for treatment choice
independently from known predictors and prognosticators. Validation in larger prospective studies is warranted.
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Background
In 2014, the estimated number of deaths from breast
cancer in Europe is 89,300 [1] and 40,000 in the US [2].
Every uncontrolled primary tumor comprises the risk of
subsequent metastatic disease, and the younger the pa-
tient, the more likely she will die from it. A long-term
analysis by the Early Breast Cancer Trialist Group
(EBCTG) showed a 4:1 relation: if four local relapses can
be avoided at year 10, one breast cancer-specific death
can be avoided at year 15 [3, 4]. Due to advances in all
disciplines related to breast conserving therapy (BCT),
the local relapse rate is generally low, with age still
appearing as the most important prognosticator and pre-
dictor for local relapse. Nowadays, the estimates for age
adjusted annual in-breast recurrence rates are 0.4–0.7 %
for patients >50 years, 0.72–1.2 % in the age group 41–
50 years, and 0.72–2 % for patients younger than
40 years, respectively [5–7].
Additionally, many other patient- and therapy-related
factors as well as molecular markers have been described
to influence clinical outcome [8–10]. Seventy percent of
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invasive breast cancers show increased expression of the
estrogen receptor α (ER-α). Up-regulation of ER-α is an
early event in tumorigenesis and cancer progression
[11, 12]. In recent years, microRNAs (miRs) were de-
scribed as potential prognosticators and predictors for
breast cancer. MiRs are short non-coding RNAs (21–
25 nucleotides), which play a role in human cancer de-
velopment both as oncogenes and tumor suppressors.
More than 50 % of the known miR genes are located
in genetically altered regions of the genome [13]. In
2005, Iorio et al. suggested a miR signature for breast
cancer. This panel of de-regulated miRs correlated
with known clinical and biological features such as
hormonal receptor status, tumor size, lymph node sta-
tus, vascular invasion, proliferation index, and p53
[14]. Recently, scientific interest has partially focused
on the connection between miRs and hormone recep-
tors [15–20]. About 15 miRs have been identified as
regulators of ER-α [21].
Thus far, only one clinical study investigated the role
of miRs with respect to local control (LC) in early stage
breast cancer [22]. Zhou et al. showed that hsa-miR-9
could discriminate between patients with and without
local relapse. Interestingly, the effect was most pro-
nounced in ER-α positive patients. In order to further
elucidate the importance of miRs for LC in early stage
breast cancer, the aim of the current study was to iden-
tify miRs that can differentiate between patients with
and without local relapse after BCT. This is especially




Potentially prognostic characteristics were distributed
without significant differences between relapse and con-
trol groups (Table 1). The median follow-up in the pilot
cohort was 126 months (range 26–200 months), and in
the validation cohort, it was 136 months (range 17–
207 months). The median time to local relapse was
37 months (range 15–123 months) in the pilot cohort
and 74 months (range 35–185 months) in the validation
cohort (Table 2).
Pilot phase
In the pilot study, five miRs showed a significant fold
change between relapse patients and their controls
(linear models for microarray analysis (LIMMA), raw
p value <0.05): hsa-miR-362-3p, hsa-miR-660, hsa-
miR-375, hsa-miR-223, and hsa-miR-125a-3p. Three
miRs had a fold change (relapse versus control) that
was close to significance (LIMMA, raw p value = 0.05):
hsa-miR-532-3p, hsa-miR-487b, and hsa-miR-210.
Hierarchical clustering of these eight miRs revealed
two main groups with different miR-expression pat-
terns (Fig. 1). One group only consisted of controls
(pattern B), while relapse patients formed the majority
of the other group (pattern A). The log-rank compari-
son revealed a significant p value of 0.002 (Fig. 2). The
levels of hsa-miR-375 were significantly higher in the re-
lapse group, with a raw p value of 0.009 (LIMMA) and a
fold change of 2.97 between relapse and controls, which is
illustrated in (Additional file 1: Figure S2). The microarray
data were deposited in NCBI Gene Expression Omnibus
under the accession number GSE69951; they can be
accessed via the following link: http://www.ncbi.nlm.nih.-
gov/geo/query/acc.cgi?acc=GSE69951.
Validation phase
For further validation, we selected the eight miRs that
were able to differentiate between relapse and controls
in the hierarchical cluster analysis. Of these eight candi-
date miRs, hsa-miR-375 could be validated by reverse
transcription quantitative polymerase chain reaction
(RT-qPCR), in the sense that it was able to differentiate
between relapse and control group in an independent
patient cohort (Table 3). The levels of hsa-miR-375 wer-
e—similar to the pilot phase—significantly higher in the
relapse group compared to controls (Mann-Whitney U
test, raw p value = 0.001; p value corrected according to
Bonferroni = 0.008) with a median fold change of 2.28
(Table 3). The box plot in Fig. 3 shows the elevated
levels of hsa-miR-375 in relapse patients compared to
controls (Fig. 3). In the log-rank analysis (event = local
relapse), high expression levels of hsa-miR-375 corre-
lated to a significantly increased risk of local relapse
(p value = 0.003; Fig. 4a). When tested in the multi-
variate analysis (forward stepwise regression) together
with the patient- and treatment-related parameters
listed in Table 1, hsa-miR-375 was the only variable
that was able to distinguish the statistical significance
between the relapse and control groups (raw p value =
0.000195 HR = 0.76, 95 % CI 0.66–0.88; p value cor-
rected according to Bonferroni = 0.005).
In the subgroup of ER-α-positive patients, the differ-
ence in hsa-miR-375 levels between the relapse and
control patients was also significant (p value = 0.001,
Mann-Whitney U test), whereas in ER-α-negative pa-
tients, it was not (p = 0.495, Mann-Whitney U test).
The log-rank analysis (event = local relapse) showed
that high expression levels of hsa-miR-375 correlated to
a higher probability of local relapse, which was more
significant than in the whole patient cohort (p = 0.0005,
see Fig. 4b).
The comparison of the hsa-miR-375 levels in ER-α-
positive to triple negative patients showed a fold change
of 4.17 (p value = 0.24, Mann-Whitney U test). Further
subgroup comparisons showed that the levels of hsa-
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Table 1 Patient and treatment characteristics
Patient and treatment characteristics
Parameters Pilot phase n = 32 Validation phase n = 115
Relapse n = 16 Control n = 16 p value Relapse n = 30 Control n = 85 p value
Age at diagnosis (years) Median 53.5 52 0.88 52 54 0.59
Range 36–71 35–74 33–79 37–78
Menopause (n) No 4 (25 %) 4 (25 %) 1.0 11 (36.7 %) 32 (37.6 %) 0.37
Yes 8 (50 %) 8 (50 %) 17 (56.7 %) 40 (47.1 %)
Unclear 4 (25 %) 4 (25 %) 2 (6.7 %) 13 (15.3 %)
T (n) T1 10 (62.5 %) 10 (62.5 %) 1.0 26 (86.7 %) 75 (88.2 %) 0.82
T2 6 (37.5 %) 6 (37.5 %) 4 (13.3 %) 10 (11.8 %)
N (n) N0 13 (81.3 %) 13 (81.3 %) 1.0 24 (80 %) 67 (78.8 %) 0.88
N1 2 (12.5 %) 2 (12.5 %) 6 (20 %) 18 (21.1 %)
N2 1 (6.3 %) 1 (6.3 %) 0 0
M (n) M0 16 (100 %) 16 (100 %) 1.0 30 (100 %) 85 (100 %) 1.0
M1 0 0 0 0
Grading (n) G1 1 (6.3 %) 0 0.87 3 (10 %) 8 (9.4 %) 0.75
G2 8 (50 %) 9 (56.3 %) 18 (60 %) 55 (64.7 %)
G3 7 (43.8 %) 7 (43.8 %) 9 (30 %) 22 (25.9 %)
Histology (n) IDC 13 (81.3 %) 15 (93.8 %) 0.56 22 (73.3 %) 63 (74.1 %) 0.98
ILC 3 (18.8 %) 1 (6.3 %) 5 (16.7 %) 12 (14.1 %)
Tubular 0 0 2 (6.7 %) 6 (7.1 %)
Other 0 0 1 (3.3 %) 4 (4.7 %)
In situ component (n) Yes 14 (87.5 %) 10 (62.5 %) 0.24 17 (56.7 %) 47 (55.3 %) 0.97
No 2 (12.5 %) 6 (6.25 %) 13 (43.3 %) 35 (41.2 %)
Lymphangiosis 0 0 0 1 (1.2 %)
Not stated 0 0 0 2 (2.4 %)
Receptors (n) ER positive 8 (50 %) 10 (62.5 %) 0.56 23 (76 %) 67 (78.8 %) 0.81
ER negative 8 (50 %) 6 (37.5 %) 7 (23.3 %) 18 (21.2 %)
PR positive 8 (50 %) 8 (50 %) 0.56 19 (63.3 %) 62 (72.9 %) 0.32
PR negative 8 (50 %) 8 (50 %) 11 (36.7 %) 23 (27.1 %)
her2neu Positive 8 (50 %) 4 (25 %) 0.24 11 (37 %) 24 (28 %) 0.81
Negative 5 (31 %) 9 (56 %) 18 (60 %) 44 (52 %)
Not assessable 3 (19 %) 3 (19 %) 1 (3 %) 17 (20 %)
Proliferation index ki67 < 20 % 10 (63 %) 6 (38 %) 0.24 15 (50 %) 49 (58 %) 0.78
ki67 > 20 % 5 (31 %) 9 (56 %) 10 (33 %) 26 (31 %)
Not assessable 1 (6 %) 1 (6 %) 5 (17 %) 10 (11 %)
Boost (n) Intraoperative 8 (50 %) 8 (50 %) 1.0 11 (36.7 %) 34 (40 %) 0.91
Percutaneous 8 (50 %) 8 (50 %) 16 (53.3 %) 51 (60 %)
None 0 0 3 (10 %) 0
Boost dose (Gy) Dose intraoperative 10 Gy 10 Gy 0.84 10 Gy 10 Gy 0.58
Dose percutaneous 12 Gy 12 Gy 12 (15–19) Gy 12 (9–19) Gy
WBRT dose (Gy) Median 54 Gy 54 Gy 0.78 54 Gy 54 Gy 0.68
Range 51.2–61.2 Gy 51.2–57.8 Gy 51–63 Gy 51–57.6 Gy
Surgery (n) BCT 16 (100 %) 15 (93.8 %) 0.78 30 (100 %) 85 (100 %) 1.0
Mastectomy 0 1 (6.3 %) 0 0
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miR-375 were higher in the ER-α-positive patients com-
pared to those in the ER-α-negative patients but without
significance (p value 0.53). The same applies to her2-
negative patients compared with her2-positive patients
1.52 (p value 0.66). For further details, please see Add-
itional file 2: Table S2.
External validation
Hsa-miR-375 was cross-validated in randomly selected
samples of five relapses and their 14 corresponding con-
trols from the validation cohort. The result of the first
validation step concerning hsa-miR-375 could be verified
with a median fold change of 2.84 and a p value of 0.019
(Mann-Whitney U test).
Discussion
Although the clinical outcome in early stage breast can-
cer patients is generally good, some patients experience
local relapse after BCT. Apart from clinical features,
biomarkers can add to the optimal treatment choice. In
the current study, we were able to identify and validate
hsa-miR-375 as a potential predictor for LC after BCT.
Our results allow us to assume that patients with high
levels of hsa-miR-375 in the primary tumor have an in-
creased risk of local relapse. Therefore, hsa-miR-375 is a
new potential predictor for LC in early stage breast can-
cer independent of the known clinical and molecular
markers. It could also become an additional selection
tool for the choice of primary operative treatment. Pa-
tients with a high level of hsa-miR-375 show a higher
risk of local relapse; however, threshold values have yet
to be defined before clinical translation. These patients
might be possible candidates for more aggressive local
treatment, i.e., mastectomy or dose-intensified adjuvant
radiotherapy following breast conserving surgery.
The first study to show that miRs in general play a
role in breast cancer was published by Iorio and col-
leagues. The authors compared miR-expression levels
Table 1 Patient and treatment characteristics (Continued)
Re-Excisition (n) Yes 8 (50 %) 4 (25 %) 0.24 12 (40 %) 33 (38.8 %) 0.91
No 8 (50 %) 12 (75 %) 18 (60 %) 52 (61.2 %)
Year of surgery (n) Before 1998 5 (31.3 %) 5 (31.3 %) 1.0 14 (46.7 %) 38 (44.7 %) 0.85
Since 1998 11 (68.8 %) 11 (68.8 %) 16 (53.3 %) 47 (55.3 %)
Chemotherapy (n) Yes 8 (50 %) 6 (37.5 %) 0.56 11 (36.7 %) 20 (23.5 %) 0.18
No 8 (50 %) 10 (62.5 %) 19 (63.3 %) 65 (76.5 %)
Hormonal treatment (n) Yes 8 (50 %) 7 (43.8 %) 0.78 16 (53.3 %) 56 (65.9 %) 0.27
No 8 (50 %) 9 (56.3 %) 13 (43.3 %) 26 (30.6 %)
Unclear 0 0 1 (3.3 %) 3 (3.5 %)
Tumor burden in biopsy (%) Median 70 50 0.34 70 50 0.52
Range 10–90 10–90 10–90 10–90
Patient and treatment characteristics as well as the relative tumor burden in the samples are shown. The relapse group and control were compared with the Mann-Whitney
U test. Neither in the pilot nor in the validation phase statistically significant differences of potentially prognostic parameters were detected between the relapse and the
control group. The stainings for her2 and ki-67 were performed according to the standard procedures implemented at the Department of Pathology. Because some of the
specimens were quite old (minimum 5 years) in some cases, the stainings—even on repetition—did not yield valid result due to technical problems with the non-adhesive
FFPE sections
Table 2 Follow-up and clinical outcome
Clinical outcome
Parameters Pilot phase n = 32 Validation phase n = 115
Relapse n = 16 Control n = 16 Relapse n = 30 Control n = 85
Time to local relapse (months) Median 37 x 74 x
Range 15–123 x 35–185 x
Time to distant metastasis (months) Median 61 x 70 49.5
Range 20–96 x 27–118 9–109
Follow-up (months) Median 121.5 130.5 125 140
Range 26–192 72–200 44–214 17–207
Lost to follow-up (n) 0 0 0 1 (1.2 %)
Cancer specific deaths (n) 4 (25 %) 0 7 (23.3 %) 2 (2.4 %)
Summary follow-up and clinical outcome in the pilot and validation phases
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by microarray technology in 76 primary tumors ver-
sus 34 normal tissues and identified a set of 15 miRs
that could differentiate between tumor and normal
tissue with 100 % accuracy [14].
Recent studies have focused on the relationship be-
tween ER-α and miR-expression levels. This is of import-
ance for the current study since 80 % of the 147 patients
we analyzed were ER-α positive. Profiling studies identi-
fied numerous miRs that are associated with either ER-
α-positive or ER-α-negative tumors [14, 23–26]. The
web of miRs involved in the regulation of the estrogen
receptor activity is complex. One of these is hsa-miR-
375, which plays a role in various types of cancer such
as prostate [27], stomach [28], lung [29], and pancreas
[30]. A connection between hsa-miR-375 and ER-α
positivity was described in vitro [11, 31], in an inter-
ventional study in rodents [12] as well as in the
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Fig. 1 By means of hierarchical clustering, a heat-map was generated. The dendrogram on top depicts the grouping of patients according to their
pattern of candidate miRs (yellow: patient with local relapse; blue: patient without local relapse). The intensity values of a given miR are shown in
green (low intensity) and red (high intensity). On the right side, the eight candidate miRs are listed. At the bottom, the sample numbers are shown.
The first knot in the dendrogram separates a group of patients without relapse (pattern B) from the rest of the cohort (pattern A)
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progression from normal tissue through lobular car-
cinoma in situ (LCIS) to invasive lobular carcinoma
(ILC) [35].
Souza et al. compared the profiles of miRs and mRNA in
cell culture. Inhibition of hsa-miR-375 reduced ER-α activa-
tion and cell proliferation. Dexamethasone-induced RAS-
related protein 1 (RASD1) was found to be a direct target
of hsa-miR-375, which negatively regulates ER-α expres-
sion. Hsa-miR-375 was up-regulated in ER-α-positive cells
compared to ER-α-negative cells and normal cells. This led
to the assumption that up-regulation of hsa-miR-375 is
both a key driver of proliferation and an early event in
tumorigenesis in ER-α positive tissues [34].
In an interventional study in rodents, Munagala
et al. could verify the correlation between hsa-miR-
375 and ER-α. ACI (August-Copenhagen-Irish) rats
were treated with estradiol alone, its inhibitor ellagic
acid alone, and estradiol + ellagic acid. ER-α was found
Fig. 2 This plot shows the log-rank comparison of pattern A versus pattern B. The pattern of eight miRs (hsa-miR-362-3p, hsa-miR-532-3p, hsa-miR-
487b, hsa-miR-660, hsa-miR-210, hsa-miR-375, hsa-miR-223, hsa-miR-125a-3p) was able to differentiate between relapse group and control group
Table 3 Summary and comparison of fold change, ΔCt values, and PCR efficiency
Pilot phase Validation phase












hsa-miR-660 0.77 5.13 7.31 4.53 2.00 <0.001 <0.001
hsa-miR-375 2.97 3.24 4.43 2.28 1.89 0.001 0.008
hsa-miR-125a-3p 1.26 6.79 6.91 1.09 2.02 0.448 1.000
hsa-miR-362-3p 0.80 7.25 7.82 1.48 1.98 0.093 0.744
hsa-miR-210 0.51 6.15 5.21 0.52 1.95 0.121 1.000
hsa-miR-223 0.58 2.81 3.13 1.25 1.98 0.806 1.000
hsa-miR-487b 1.22 6.93 7.30 1.29 2.10 0.373 1.000
hsa-miR-532-3p 0.90 6.22 6.30 1.05 2.15 0.679 1.000
Eight candidate miRs were selected in the pilot phase and further analyzed in an independent cohort by RT-qPCR. Both in the pilot and the validation cohort, the levels
of hsa-miR-375 were significantly higher in the relapse group (raw p value = 0.001, corrected p value = 0.008). For calculation of the relative miR expression, the Ct values
of the reference gene were subtracted from the Ct values of the target miR. The fold change was estimated with the ΔΔCt method as described by Livak. Correlations
were tested for statistical significance with the non-parametric Mann-Whitney test, p values were corrected for multiple testing according to Bonferroni
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to be regulated—among other miRs—by hsa-miR-375.
In estradiol-treated cancers, up-regulation of hsa-
miR-375 is common and can be reversed by ellagic
acid [12, 36].
Ward et al. combined in vitro data with retrospective
clinical results. Hsa-miR-375 was found to be down-
regulated in Tamoxifen resistant cells. Its re-expression
reverses both Tamoxifen resistance and accompanying
epithelial-mesenchymal transition (EMT)-like properties
in breast cancer. The levels of metadherin (MTDH), a
direct target of hsa-miR-375, were measured in patients
and correlated inversely with disease-free survival [31].
Hoppe et al. described the connection between miR pro-
files, ER-α status, and Tamoxifen resistance in postmen-
opausal patients. Low levels of hsa-miR-375 predicted
worse relapse free time, but as opposed to hsa-miR-10a
and hsa-miR-126, this effect was not statistically signifi-
cant [32]. Lyng et al. conducted a similar study in 152
patients with ER-α-positive tumors. Distant recurrence
was the statistical endpoint. Of note, patients in the pilot
set were matched according to their clinical features,
whereas patients in the two validation sets were
randomly selected. None of the miRs in the pilot set
overlapped with the miRs in the validation sets, and
the only statistically highly significant difference be-
tween the group of recurrent and non-recurrent pa-
tients was the number of tumor-infiltrated lymph
nodes [33]. Jonsdottir correlated miR profiles with
known clinicopathological factors in 204 lymph node-
negative patients with distant metastasis-free survival.
Hsa-miR-375 levels were high in ER-α-positive pa-
tients. As opposed to hsa-miR-106, hsa-miR-375 was
unable to differentiate between patients with or with-
out distant metastases [34]. Giricz et al. investigated
hsa-miR-375 in normal tissue, lobular carcinoma in
situ and invasive lobular carcinoma (ILC) in formalin-
fixed paraffin-embedded (FFPE) specimens of 31 pa-
tients and in vitro. The highest levels of hsa-miR-375
were detected in ILC and LCIS adjacent to ILC. Their
gene transfer experiments revealed that induced eleva-
tion of this microRNA to levels found in human
lobular breast cancer specimens changes the ability to
maintain appropriate tissue organization. The authors
conclude that high levels of hsa-miR-375 contribute to
progression from normal tissue to ILC [35]. Since over
90 % [35] of ILC are ER-α-positive, there seems to be
Fig. 3 Hsa-miR-375 was the most prominent miR to differentiate between relapse and control group. The y-axis shows the ΔCt values of hsa-miR-375
in relapse and control group; therefore, a high ΔCt value means low expression of hsa-miR-375
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a functional connection between ER-α overexpression
and elevated levels of hsa-miR-375 as described by
Souza et al. [11].
Thus far, the only study with LC as statistical endpoint
was performed by Zhou in a cohort of 68 patients. Only
FFPE samples with a tumor burden of at least 70 % were
included in the analysis. Hsa-miR-9 was able to differen-
tiate between patients with and without local relapse.
Hsa-miR-375 was one of the candidate molecules se-
lected in the pilot phase but was finally unable to predict
Fig. 4 a In a time-to-event analysis (event = local relapse), hsa-miR-375 was able to separate the relapse from the control group (log-rank p= 0.003): high
expression levels were correlated with a higher probability of local relapse. b In a subgroup analysis of only ERα-positive patients, the differentiation
between relapse and control based on the levels of hsa-miR-375 was more pronounced (log-rank p= 0.0005)
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LC in the patients of the validation set. Nevertheless, the
authors found a strong correlation between hsa-miR-375
and ER-α status [22].
Taken together, these studies show that to date, it re-
mains a matter of debate whether hsa-miR-375 is of pre-
dictive and/or prognostic relevance for early stage breast
cancer. In accordance with Jonsdottir et al., our results
also show that high levels of hsa-miR-375 lead to a
worse outcome [34]. The effect is particularly pro-
nounced in ER-α-positive patients, which coincides with
the mechanistic evidence provided by Souza et al. [11].
Discrepancies between our analysis and literature may
be explained by our focus on LC in early stage breast
cancer. Different clinical settings result in different stat-
istical endpoints, such as disease-free survival and may
therefore lead to diverging results. Additionally, sample-
related differences may be important. (1) The current
study compares tumor tissues with each other, which
means that the difference in the miR levels of relapse
versus controls must be large to be detected. Iorio et al.,
e.g., compare normal and tumor tissues [14]. (2) Some
studies were performed after microdissection of the spe-
cimen [22, 34], whereas in the present analysis, tumor
tissue contains stroma. This strategy is based on daily
clinical procedures and therefore feasible in diagnostic
routine without additional manipulation of the speci-
men, which adds to the robustness of our results. (3)
Whole tissue sections were used in the present analysis
since we believe that a given miR—if clinically relevant
as a predictor and/or prognosticator—should be able to
differentiate between patients even if the tumor cell con-
tent is small.
However, a limitation of our study concept is that the
cellular signal is either from stromal or tumor tissue.
Moreover, there is no validated endogenous reference
gene available for breast cancer [37–39]. According to
literature, the standard approach is to use small nuclear
or small nucleolar RNAs as controls. The reference gene
we used was SNORD-61, a small nucleolar RNA, which
was validated by Spervelage for neuro-endocrine tumors
of the ileum [38].
Beyond the scope of the current analysis, it is import-
ant to further elucidate the oncogenic interference of
hsa-miR-375 in cancer pathways. This entails in particu-
lar the necessity to define mRNA molecules, which con-
tain potential binding sites for hsa-miR-375. In theory,
the result would be a down-regulation of a tumor sup-
pressive protein. Our search in five different databases
(TargetScan, miRDB, PITA, DIANA, DIANA Cancer)
performed in May 2015 resulted in a large variety of
potential target molecules. We chose the results given
by TargetScan and PITA for two reasons. First, it is
generally recommended to select overlapping results
from databases that implement different algorithms [40].
Second, these two databases provide a reasonable num-
ber of potential targets. TargetScan (Release 6.2) identi-
fied 229 putative mRNA targets based on their
conserved complementarities to the seed region of the
miR [41]. PITA additionally includes secondary struc-
tures and binding energies for prediction [42], which
consequently resulted in a smaller number of 116 poten-
tial targets (Additional file 3). The comparison of both
databases revealed 15 overlaps. Among these, we identi-
fied one gene that has been validated experimentally
by reporter gene assay in breast cancer cells: RASD1
[11]. It belongs to the Ras superfamily of small G pro-
teins, but it does not share key residues in reactive
domains with other Ras family members, such as V-
Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
(KRAS), transforming protein p21 (HRAS), and neuro-
blastoma ras viral oncogene homolog (NRAS). As op-
posed to these structurally related molecules, RASD1
inhibits clonal cell expansion suggesting a tumor
suppressive role [43]. Additionally, we used the Gene-
CoDis software [44] to correlate this predicted target
with cancer pathways (Panther classification system).
According to this analysis, RASD1 is related to the
PI3K-pathway (Additional file 4). The involvement in
known cancer pathways and its experimental valid-
ation as a direct target of hsa-miR-375 makes RASD1
a promising candidate for further evaluation and
underlines the potential biological significance of hsa-
miR-375 in early stage breast cancer.
Conclusions
In summary, we could show that high levels of hsa-miR-
375 are associated with a significantly higher probability
of local relapse, especially in ER-α-positive patients.
Hence, hsa-miR-375 is an independent predictor for
local treatment outcome after breast conserving therapy.
Although our results require validation in larger pro-
spective studies, we suggest hsa-miR-375 as an add-




Between October 1998 and October 2012, 5093 patients
were treated for breast cancer at the Department of
Radiation Oncology at the Paracelsus Medical Univer-
sity, Salzburg. For the current study, 147 breast cancer
patients were selected. According to the 7th edition of
the TNM/AJCC classification system, early stage breast
cancer includes I, IIA, and IIB (T2 N1). 145/147 (99 %)
patients in the current study are in one of this disease
stage. 2/147 (1 %) patients (one relapse patient and her
matched control) in the pilot cohort had N2 disease.
All patients gave their informed consent for surgery,
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radiotherapy, and systemic treatment. Patients with
local relapse were matched to controls without local
relapse. Local relapse was defined as re-appearance of
the invasive cancer in the same breast, regardless of
whether the invasive tumor re-appeared within the
former index quadrant, defined by the tumor bed with
a 3-cm margin, or not [45–47]. Patients who showed
no radiological and histological evidence of local re-
lapse were defined as locally controlled. The study co-
hort comprised 46 in-breast relapses (in and out
quadrant) and 101 matched controls. The patients in
our study were selected based on the following criteria:
(1) invasive carcinoma; (2) minimum follow-up of five
years; (3) the tumor specimen had to be processed by
the Department of Pathology at the Paracelsus Medical
University; and (4) sufficient FFPE material. Patients
were matched according to the year of diagnosis, the
type of surgery (mastectomy or lumpectomy), the type
of radiotherapy (whole-breast irradiation with percu-
taneous or intraoperative boost), age, tumor size, lymph
node involvement, grading, histology, hormonal recep-
tor status, her2 status, menopausal status, and Ki67
proliferation index. The study was approved by the
local ethics committee in Salzburg (Ethikkommission
für das Bundesland Salzburg 415-EP/73/85-2012).
Experimental design
The study was conducted in a pilot and a validation
phase. In the pilot phase, primary tumors of 32 patients
(16 patients who experienced a local relapse versus 16
matched controls who had no relapse) were screened for
the most de-regulated miRs by means of a commercially
available microarray (Agilent™ Sure Print). This part of
the study was carried out by the Comprehensive Bio-
marker Center™ in Heidelberg. Candidate miRs were se-
lected according to their fold changes (i.e., the ratio of a
miR levels in patients with local relapse to those with-
out), and their statistical significance was estimated with
the moderated t test (LIMMA).
The validation study in an independent cohort was
performed in primary tumor tissue of 115 patients and
consisted of two steps. In the first step, the candidate
miRs were analyzed in 30 patients with local relapse
compared to 85 matched controls without relapse. This
step was performed by the Laboratory of Molecular
Pathology at the Department of Pathology, Paracelsus
Medical University, Salzburg. The expression levels of these
candidate miRs were assessed with RT-qPCR. In the second
step, these results were cross-validated in 19 patients (5 re-
lapses versus 14 matched controls) randomly selected from
the validation cohort of 115 patients. This part of the
analysis was done at the Department of Pathology of the
Ludwig Maximilian University in Munich on a technically
different RT-qPCR platform. The experimental design is
summarized in the study flow-chart (Additional file 5).
Samples
Surgical samples were FFPE and archived in the tissue
bank of the Department of Pathology at the Paracelsus
Medical University, Salzburg. Apart from routine proce-
dures applied to clinical samples, no additional process-
ing was performed. For the current analysis, the whole
tissue sections with a maximum proportion of tumor tis-
sue were selected. The tumor burden in the biopsies
ranged from 10 to 90 % (see Table 1).
Pilot phase: microarray
By means of microarray technology, a panel of 1250
miRs was screened. For this purpose, the FFPE sam-
ples of the primary tumors were retrieved from the
tissue bank, and seven consecutive sections per patient
were prepared (depending on tissue size, the thickness
of the sections was 2 to 4 μm). Isolation of total miR
and chip-based microarrays (Agilent’s Sure PrintG3
Human miRNA microarrays™) were performed accord-
ing to standard procedures by the Comprehensive Bio-
marker CenterTM, Heidelberg.
Validation phase: RT-qPCR
RNA extraction and reverse transcription
Routinely, we used seven sections with a 10-μm thickness
for RNA extraction with the miRNeasy FFPE kit
(QiagenTM) according to the manufacturer’s instructions.
Each sample was treated with DNase I (included in the kit)
to avoid DNA contamination. The RNA was eluted in 20 μl
water and stored at −80 °C. For RNA quantification, the
Qubit™ RNA Assay Kit (InvitrogenTM) was used. One hun-
dred thirty nanogram of RNA were reversely transcribed
using miScript II RT Kit (QiagenTM) in a total volume of
20 μl. Each reaction was incubated at 37 °C for 60 min and
heat-inactivated at 95 °C for 5 min. The complementary
DNA (cDNA) was stored at −20 °C until further use.
Real-time PCR
Expression levels of candidate miRs were measured by
miScript SYBR Green PCR Kit (QiagenTM). Specific
PCR target information is provided in Additional file
6: Table S1. The primer assays for each target miR and
SNORD61 (catalog number MS00033705) were pur-
chased from QiagenTM. The reaction set up was 0.1 μl
cDNA, 1 μl 10× miScript Universal Primer, 5 μl Quanti-
Tect SYBR Green PCR master mix, and 1 μl Primer miS-
cript Primer assay in a total reaction volume of 10 μl.
Following the initial activation step at 95 °C for 15 min,
the cycling conditions were 40 times 15 s 94 °C, 30 s at
55 °C, and 30 s at 70 °C. All PCR reactions were per-
formed in technical duplicates.
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qPCR validation
The PCR data were analyzed with the Rotor-Gene
2.0.2.4 software (QiagenTM) according to the suggestions
of MIQE guidelines (minimum information for publica-
tion of quantitative real-time PCR experiments) [48]. To
test the PCR specificity, every reaction was subjected to
melting curve analyses. The amplification efficiency of
each primer pair was determined by a qPCR assay using
a series of 1:5 dilutions of cDNA from the control sam-
ples. Each reaction was performed in triplicates. The
slope of the resulting standard curve was used to calcu-
late the PCR efficiency according to the following
formula: efficiency = 10(−1/slope).
Data analysis
The Ct value of the reference gene was subtracted from
the Ct value of a given miR to receive the ΔCt value.
Subsequently, the median of all ΔCt values was calcu-
lated. The median of the control group was subtracted
from the median of the relapse group to receive a ΔΔCt
value. The fold change was calculated with the ΔΔCt
method [49]. The non-parametric Mann-Whitney U test
was used to compare the ΔCt values of relapse and con-
trol groups. Raw p values were corrected for multiple
testing according to Bonferroni.
External validation
This second validation step on a technically different
platform was performed with the sole purpose of verify-
ing the results of the first validation step; therefore,
only hsa-miR-375 was analyzed in this cohort of 19 ran-
domly selected patients. SNORD61 was used as the ref-
erence gene.
SNORD61 expression analysis
Reverse transcription of 100 ng total RNA was carried
out using the RevertAid First Strand cDNA Synthesis
Kit (Thermo ScientificTM), according to the instructions
of the manufacturer. RT-qPCR analyses were performed
on a LightCycler 480 instrument using the TaqMan
Gene Expression Assay (Life TechnologiesTM) following
the instructions of the manual. Briefly, the final reaction
mix contained 2 ng cDNA, 1× TaqMan Gene Expression
Assay, and 1× TaqMan Gene Expression Mastermix II,
no UNG. Single qPCRs analyses were run in duplicates.
Hsa-miR-375 expression analysis
Reverse transcription reactions were performed using
the TaqMan™ Reverse Transcription Kit (Life Technolo-
giesTM) according to the manufacturer’s instructions. For
single RT reactions, miR-specific RT primers were used
and miRs were converted into cDNA in one reaction
using 10 ng total RNA. cDNA templates were analyzed
applying the TaqMan Small RNA Assay for hsa-miR-
375, following the instructions of the manufacturer. Re-
action Mixes contained 1× TaqMan Gene Expression
Mastermix II, no UNG, 1× TaqMan miRNA assay, and a
1:15 dilution of the RT product. The temperature profile
was as follows: 10 min at 95 °C, followed by 40 cycles of
95 °C for 15 s, and 60 °C for 1 min. All samples were an-
alyzed in duplicate reactions. The relative expression of
the miRs was calculated by the ΔΔCt comparative
threshold method [49].
Statistics
In the pilot phase, differentially expressed miRs were
selected as candidates for further validation according to
their fold change and its statistical significance
estimated with the moderated t test (LIMMA) [50].
Raw p values were adjusted for multiple testing ac-
cording to Benjamini-Hochberg [51]. In order to avoid
losing any biomarker with possibly discriminative po-
tential, this rather weak correction method was ap-
plied on purpose in the pilot phase. We tried to detect
possible clusters in rows (miRs) and columns (sam-
ples) of the normalized expression matrix by hierarch-
ical clustering (bottom-up complete linkage clustering
using the Euclidean distance as a measure). The den-
drogram on top of the expression matrix demonstrates
samples which cluster together. Thereby, a miR pat-
tern could be defined that differentiates patients with
and without local relapse.
In the validation phase, the Mann-Whitney U test
was used to compare ΔCt values, patient-, tumor-, and
treatment-related characteristics between groups for
statistically significant differences. LC was estimated
with the Kaplan-Meier method. The comparison of
time-to-event analyses in dependence of differentially
expressed miR levels was performed with the log-rank
test. Local relapse was defined as an event (= in-breast
recurrence). Multivariate analyses were performed with
the forward stepwise regression (Cox regression). A raw p
value <0.05 was considered significant. To adjust for mul-
tiple testing, the rather strict Bonferroni correction was
applied in this phase of the study in order to test potential
markers for statistical robustness [52].
Additional files
Additional file 1: Figure S1. Comparison of hsa-miR-375 levels in the
pilot study. The most prominent single miR that could differentiate
relapse from control patients was hsa-miR-375 (LIMMA, raw p value
0.009). The box plot shows relapse versus control group, and the
expression values of hsa-miR-375 are shown on the y-axis. (PDF 24.3 kb)
Additional file 2: Table S2. Comparison of subgroups according to
receptor status. This table shows that in ER-α+ patients, the levels of hsa-miR-
375 are higher than in TNBC and ERα− patients, with fold changes of 1.87 and
4.17. The p value was estimated with the non-parametric Mann-Whitney U
test. None of the fold changes is significant. The group of her2-negative
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patients has slightly higher levels of hsa-miR-375 than the her2-positive patient
group, again the difference is not significant. (PDF 124 kb)
Additional file 3: Figure S3. Target prediction for hsa-miR-375. The Venn
diagram shows the number of predicted targets from TargetScan (blue)
http://www.targetscan.org/and PITA (red) http://genie.weizmann.ac.il/pubs/
mir07/mir07_data.html; 15 genes were suggested by both algorithms.
(PDF 44.5 kb)
Additional file 4: Figure S4. Predicted targets of hsa-miR-375 and cancer
pathways. Gene enrichment analysis of the predicted targets by GeneCoDis3
software (http://genecodis.cnb.csic.es/). RASD1 was assigned to the PI3K-
pathway (http://www.pantherdb.org/pathway/). The numbers on the x-axis
indicate how many of the 15 “overlapping” genes in Additional file 3: Figure
S3 are found in a specific pathway. (PDF 20.2 kb)
Additional file 5: Figure S1. Study flow-chart. This additional file shows
the various steps of the study. (PDF 42.8 kb)
Additional file 6: Table S1. RT-qPCR target information. This table
provides information on the exact sequences of the primers that were
used for RT-qPCR including the Qiagen™ catalog number. (PDF 29.9 kb)
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